491 studies found for:    Open Studies | Exclude Unknown | "neurological disorders"OR"brain tumors"OR"attention-deficit/hyperactivity disorder"OR"epilepsy"OR"chronic pain"OR"spincal cord injury"OR"stroke" | United States | Phase 1, 2, 3, 0 | Industry
Show Display Options
Rank Status Study
21 Recruiting Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
Condition: Attention Deficit Hyperactivity Disorder (ADHD)
Intervention: Drug: SPD489
22 Recruiting Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients
Condition: Chronic Pain
Intervention: Drug: Hydromorphone HCl ER Tablets
23 Recruiting A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
Conditions: Epilepsy, Partial Seizures;   Epilepsy, Primary Generalized Tonic-Clonic Seizures
Intervention: Drug: Pregabalin
24 Recruiting Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
Condition: Ischemic Stroke
Interventions: Device: The Ischemic Stroke System;   Device: Sham control
25 Recruiting Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
Condition: Epilepsy
Intervention: Drug: USL261
26 Recruiting An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study
Condition: Post-ischemic Stroke
Interventions: Drug: dalfampridine-ER 7.5 mg;   Drug: dalfampridine-ER 10 mg
27 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
28 Recruiting A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Conditions: Epilepsy;   Dravet Syndrome
Interventions: Drug: GWP42003-P;   Drug: Placebo Control
29 Recruiting Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
Conditions: Acute Repetitive Seizures;   Breakthrough Seizures
Intervention: Drug: NRL-1
30 Recruiting A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
Conditions: Dravet Syndrome;   Seizure Disorder
Interventions: Drug: ZX008 (Fenfluramine Hydrochloride);   Drug: Matching Placebo
31 Recruiting Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
Conditions: Chronic Pain;   Osteoarthritis, Hip;   Osteoarthritis, Knee
Interventions: Drug: NSAID;   Biological: Tanezumab 2.5 mg;   Biological: Tanezumab 5 mg
32 Recruiting Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
Conditions: Low Back Pain;   Chronic Pain
Intervention: Drug: NKTR-181
33 Recruiting Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
Conditions: Low Back Pain;   Chronic Pain
Interventions: Drug: NKTR-181;   Drug: Placebo
34 Recruiting The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Condition: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Drug: MDX;   Drug: Placebo
35 Recruiting Staccato® Alprazolam and EEG Photoparoxysmal Response
Condition: Epilepsy
Interventions: Drug: Staccato® Alprazolam, 0.5 mg;   Drug: Staccato® Alprazolam, 1 mg;   Drug: Staccato® Alprazolam, 2 mg;   Drug: Staccato® Placebo (a);   Drug: Staccato® Placebo (b)
36 Recruiting A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
37 Recruiting Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions: Agitation Associated With;   Alzheimer's Disease;   Alzheimer's Type;   Mental Disorder;   Nervous System Diseases
Intervention: Drug: Brexpiprazole, OPC-34712
38 Recruiting MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
Condition: Brain Tumor
Intervention: Device: ExAblate transcranial system
39 Recruiting Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation
40 Recruiting Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Conditions: Attention Deficit Hyperactivity Disorder (ADHD);   Binge-Eating Disorder Disorder
Intervention: Drug: dasotraline

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years